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During this study, cats were immunized by the intranasal and rectal routes with crude rhoptry proteins of
Toxoplasma gondii admixed with Quil-A. Twenty-ﬁve domestic short hair cats divided into ﬁve groups
(n = 5) were used during this evaluation: G1 and G3 cats received 200 lg of the rhoptry proteins with
Quil-A (20 lg) by the intranasal and rectal routes, respectively; G2 and G4 cats received bovine serum
albumin (BSA, 200 lg/dose) with Quil-A (20 lg); and G5 animals served as unvaccinated controls. All
treatments were performed at days 0, 21, 42, and 63. The challenge was done with 800 cysts of the
ME49 of T. gondii strain at day 70 (challenge day). The serum IgG, IgM, IgA, and fecal IgA antibody levels
were evaluated by using the indirect enzyme-linked immunosorbent assay (ELISA). Some animals pro-
duced antibody levels beyond cut-off; however, two animals from G1 (ODmean = 0.308, ODcut-off = 0.200)
and three from G3 (ODmean = 0.254) demonstrated IgG levels on being challenged, with similar results
occurring in two cats from G1 to IgM (ODmean = 0.279, ODcut-off = 0.200). Fecal IgA levels were detected
in all G1 cats (ODmean = 0.330, ODcut-off = 0.065), and in one cat from G3 (ODmean = 0.167). The serum
and fecal humoral immune responses did not correlate with oocyst shedding. Oocyst shedding varied from
98.4% (G1), 87.5% (G2), 53.0% (G3), to 58% (G4), and was lower than that of G5 cats. The prepatent period of
cats vaccinated intranasally (G1) was reduced from 6–9.6 to 2.8 days, suggesting protection of environ-
mental contamination, considering cats as the primary source of contamination. The intranasally and
rectally administered rhoptry vaccines were able to partially protect cats against T. gondii cysts on being
challenged; however, the intranasal method of vaccination yielded better results relative to the rectal
route.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Toxoplasma gondii is a protozoan parasite that is widely distrib-
uted. Cats are the key to control T. gondii due to the fact they shed,
via feces (Dubey et al., 2004), millions of oocysts, which after spor-
ulation in the environment might infect warm-blooded animals
including human beings (Garcia, 2009). The principal source of
infection for production animals is via the ingestion of either food
or water, contaminated with sporulated oocysts liberated from the
feces of infected cats (Frenkel, 1990). Human beings can be
infected by the ingestion of sporulated oocysts, raw or uncooked
meat from animals, and vertical transmission.
The production of an effective vaccine against T. gondii is of
utmost importance to reduce the associated cost worldwide, as wellsevier OA license. as to prevent the consequences of human toxoplasmosis such as
abortions, chorioretinitis, mental retardation, and death. Addition-
ally, the reduction of oocyst shedding in cats would be a fundamen-
tal prophylactic measure, since these animals are responsible for
the dissemination of toxoplasmosis.
The saponin adjuvant Quil-A derived from the bark of the tree,
Quillaja saponaria. Quil-A is a widely used veterinary adjuvant, that
is inexpensive, simple to formulate, and generally safe (Cox and
Coulter, 1997). Smith et al. (1998) have demonstrated that the oral
administration of free Quil-A admixed with OVA resulted in most
of the local and systemic immune responses obtained with ISCOM
and OVA. Garcia et al. (2007) used crude T. gondii rhoptry proteins
admixed with Quil-A by the intranasal route to evaluate the con-
trol of oocyst shedding in domestic cats, and indicated that most
cats (66%; 2/3) did not shed oocysts after being immunized with
three doses of the vaccine, while 65% of protection was conferred
unto vaccinated cats.
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cyst shedding in cats vaccinated with the crude rhoptry proteins of
T. gondii administrated by the intranasal and rectal routes.2. Materials and methods
2.1. T. gondii strains
Two strains of T. gondii were used in this experiment: LIV-5 and
ME49. The LIV-5 strain was used for rhoptry puriﬁcation (Garcia
et al., 2004), while the ME49 strain was used for the production
of tissue cysts to challenge the cats. Tissue cysts of the ME49 strain
were obtained by infecting 10 mice with sporulated oocysts of 50
T. gondii by the oral route. These animals were euthanatized
60 days after being infected. Tissue cysts were recovered from
the brain of each mouse, counted and prepared for challenge
(ﬃ800 cysts to each cat in a total of 2 ml of saline).
2.2. T. gondii rhoptry puriﬁcation
Tachyzoites of the LIV-5 strain were obtained from the perito-
neal ﬂuid of infected Swiss mice. The obtained material was puri-
ﬁed by passed thrice through a 26 gauge needle and rinsed with
10 mM phosphate buffered saline (PBS, pH 7.5). The pellet ob-
tained was resuspended and rinsed in homogenization medium
(HM: 250 mM sucrose; 1 mM EDTA; 5 mM triethanolamine–HCl;
pH 7.5); tachyzoites were prepared at a concentration of 109 tach-
yzoites/ml. Cell suspension was disrupted in a French pressure cell
at 50 kg/cm3. Whole cells were sedimented by centrifugation
(10 min at 750g). The supernatant was centrifuged (12,000g for
10 min) to separate the crude organellar. The ﬁnal pellet was frac-
tionized by isopynic sucrose density gradient centrifugation for the
isolation rhoptries as described (Garcia et al., 2004). Brieﬂy, the ﬁ-
nal pellet was resuspended in 4 ml of HM, placed onto a 6 ml con-
tinuous 1.0–1.6 M sucrose gradient and centrifuged overnight
(72,000g). Sub-fractions were then collected from each visible gra-
dient fraction, suspended in 10 ml of HM, and pelleted by centrifu-
gation (120,000g for 1 h). Fraction 3 (1.4 M and a density of 1.17 g/
cm3) revealed rhoptries as described (Garcia et al., 2004) and was
used to vaccinate the animals. From 100 mice infected with T. gon-
dii LIV-5, 300 ml of peritoneal ﬂuid with 3  107 tachyzoites/ml
were collected from which 4600 lg of rhoptry proteins (in a total
volume of 2 ml) were obtained. Protein concentration in each
sub-fraction was determined by using the bicinchoninic acid tech-
nique (BCA protein assay reagent, Pierce).
2.3. Vaccination and challenge of cats
This study was approved by the Animal Experimentation Ethics
Committee (CEEA, protocol number 51/07), Universidade Estadual
de Londrina. Twenty-ﬁve short hair domestic cats, of both sexes,
between 3 and 6 months of age, were randomly allocated in indi-
vidual cages; all cats received only commercially prepared ration
and water ad libitum. The animals were previously monitored for
2 months prior to the beginning of the experiment. All cats were
serum negative (titer <16) for T. gondii by the indirect immunoﬂu-
orescence assay (IFA) before being immunized; the absence of T.
gondii oocysts was further conﬁrmed by fecal examination.
The cats were divided into ﬁve groups (n = 5, Table 1): G1 ani-
mals received 200 lg of rhoptry proteins with Quil-A (20 lg); G2
received 200 lg of bovine serum albumin (BSA) with Quil-A
(20 lg), the animals within both of these treatment protocols were
immunized nasally. Intranasal vaccination was achieved by
the introduction of an adapted stomach tube half-way through
the nostrils of each cat. G3 and G4 animals were subjected to thesame protocol as above, but were immunized via rectal adminis-
tration. The G5 animals served as controls. All inoculations were
performed on days 0, 21, 42, and 63 of the experiment. All animals
were anesthetized with tiletamine plus zolazepam (Zoletil, Vir-
bac, 3.15 mg/kg/IM) during which they were challenged on day
70 with 800 tissue cysts of the ME49 strain (contained in a volume
of 2 ml) administered via stomach tube, after which they were in-
jected with 5 ml of saline.
2.4. Sampling and measurements
Blood and serum samples were obtained on days 7, 0, 21, 42, 63,
70, 85, 100, and 115 of the experiment. Feces from each cat were
collected from the 2nd day until 20 days after being challenged
and examined microscopically for oocysts as described (Garcia
et al., 2007). Brieﬂy, feces obtained over a period of 24 h were di-
luted in a small volume of distillated water; 2.5 g of this material
were admixed with 10 ml of sucrose solution (speciﬁc gravity,
1.18), ﬁltered, and centrifuged (1200g for 10 min). One drop of
solution, removed from the meniscus, was examined microscopi-
cally. When oocysts were detected the supernatant was collected
(9 ml) admixed with 40 ml of water in a 50 ml tube, and centri-
fuged (1200g) for 10 min. The supernatant was discarded and the
sediment elevated to 10 ml with water. The number of oocysts
was then determined in four WBC chambers of a hemocytometer.
For challenge, 10 g of feces were collected, mixed (1:1) with PBS
containing 0.1% sodium azide, and then centrifuged (1200g) for
30 min; 1 ml of the supernatant was utilized to evaluate IgA
antibodies.
2.5. Indirect immunoﬂuorescence assay (IFA)
The presence of antibodies against T. gondii in serum samples of
cats was done at beginning of the experiment by using the indirect
immunoﬂuorescence assay (Camargo, 1974); cats with titer P16
were considered as positive for T. gondii.
2.6. Enzyme-linked immunosorbent Assay (ELISA)-IgG and IgM
The ELISA assay was performed as described (Garcia et al.,
2007). Optimal dilutions were established by using checkerboard
titrations with dilutions of sera and conjugates. Previously ob-
tained rhoptries were used as antigens to coat the ﬂat-bottom
96-well polystyrene microtitration plates (Nunc-Immuno Plate,
MaxiSorp, Denmark) with 0.1 ml of the antigens (5 lg/ml) diluted
in 0.1 M carbonate buffer (pH 9.6) by incubation overnight at 6 C.
The plates were rinsed thrice with PBS-tween 20 (50 mM tris, pH
7.4, containing 150 mM sodium chloride and 0.05% tween 20)
and non-speciﬁc immune sites were blocked by incubation for
1 h at 37 C with carbonate buffer 8% nonfat dry milk. The control
and evaluated sera were diluted (1:100) with IgG and IgM in PBS-
tween 20–5% nonfat dry milk; 0.1 ml of this mixture was added to
the wells of the microtitre plates in duplicate, and incubated for 1 h
at 37 C. After rinsing, HRP-labeled anti-cat IgG and IgM antibodies
(Bethyl Lab, Montgomery, TX, USA) were diluted (1:10.000) in PBS-
tween 20–5% nonfat dry milk, after which 0.1 ml of the mixture
was added to each well and incubated for 1 h at 37 C. After rinsing,
the peroxidase activity was revealed by adding 0.1 ml of ortho-
phenylenediamine solution (40 mg ortho-phenylenediamine/
100 ml of 0.1 M phosphate citrate buffer, pH 6.0, and 40 ll of
H2O2), and the reaction was stopped by adding 0.05 ml of 1 N
HCl. The optical density (OD) was read at 490 nm in an ELISA
microplate reader. For controls, positive and negative control sera
were included in every plate and a corrected OD value was calcu-
lated as follows:
Table 1
Experimental design of cats immunized with rhoptry proteins of T. gondii.
Experimental groups (n = 5) Vaccination route Vaccination protocols (0, 21, 42, 63 days)1 Challenge (Day 70)1
G1 Nasal 200 lg rhoptries + QuilA (20 lg) 800 cysts ME-493
G2 Nasal 200 lg BSA2 + QuilA (20 lg)
G3 Rectal 200 lg rhoptries + QuilA (20 lg)
G4 Rectal 200 lg BSA + QuilA (20 lg)
G5 Control Not vaccinated
1 Period during which procedure was realized.
2 Bovine serum albumin.
3 All groups were challenged with the same dosage and during the same day.
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 ODnegative control of plateÞ
A serum was considered to be positive when ODcorr > [OD mean
(from negative control sera, n = 11) + 2SD (standard deviation from
negative control sera)].
2.7. Enzyme-linked immunosorbent assay (ELISA)-IgA
Optimal dilutions were established by using checkerboard titra-
tions with dilutions of sera and conjugates. Previously obtained
rhoptries were used as antigen to coat the 96-well ﬂat-bottomed
polystyrene microtitration plates (Nunc-Immuno Plate, MaxiSorp,
Denmark) with 0.1 ml of the antigens (5 lg/ml) diluted in 0.1 M
carbonate buffer (pH 9.6) by incubation overnight at 6 C. The
plates were rinsed thrice with PBS-tween 20 (50 mM tris, pH 7.4,
containing 150 mM sodium chloride and 0.05% tween 20) and
non-speciﬁc immune sites were blocked by incubation for
1 h:30 min at 37 C with carbonate buffer plus 8% nonfat dry milk.
The control and evaluated sera were diluted (1:20), as well as the
supernatant from feces were diluted (1:4) to detect IgA antibodies,
PBS-tween 20 plus 5% nonfat dry milk and added to the microtitre
plates in duplicate, 0.1 ml in each well, and incubated overnight at
+6 C. After washing, HRP-goat anti-cat IgA antibody (Bethyl Lab,
Montgomery, TX, USA) were diluted 1:2.000 in PBS-tween 20–5%
nonfat dry milk, and was added 0.1 ml in each well and incubated
for 2 h at 37 C. After rinsing, HRP-rabbit anti-goat IgG antibody
(Bethyl Lab, Montgomery, TX, USA) were diluted 1:1.000 in PBS-
tween 20–5% nonfat dry milk, and was added 0.1 ml in each well
and incubated for 2 h at 37 C. After washing, the peroxidase activ-
ity was revealed by adding 0.1 ml of ortho-phenylenediamine solu-
tion (40 mg ortho-phenylenediamine/100 ml of 0.1 M phosphate
citrate buffer, pH 6.0, and 40 ll of H2O2), and the reaction was
stopped by adding 0.05 ml of 1 N HCl. The optical density (OD)
was obtained as described for the detection of IgG and IgM
antibodies.
2.8. Lymphocyte proliferation assay
At the moment of challenge, whole blood was obtained by veni-
puncture in EDTA vacutainers and homogenized (1:2) with phos-
phate-buffered saline (PBS). The peripheral blood mononuclear
cells (PBMC) were isolated by density gradient centrifugation by
using lymphocyte separation media (LSM). The isolated cells were
rinsed twice in RPMI 1640 medium (GIBCO), resuspended and pla-
ted in RPMI 1640 medium (GIBCO) supplemented with 5% fetal calf
serum, HEPES (25 mM; Sigma), L-glutamine (1 mM; BioWhittaker),
sodium pyruvate (1 mM; Sigma), b-mercaptoethanol (50 mM), and
penicillin–streptomycin (1 mM; Sigma), and then seeded at
5  105 cells per well in triplicate in ﬂat-bottomed 96-well micro-
titer plates (Costar) that contained 200 ll of either 1% concanava-
lin-A (Con-A) or 5, 10, and 15 lg of rhoptry proteins per ml. The
plates were incubated in 5% CO2 at 37 C for 4 days, and the cellswere evaluated by trypan blue until more than 90% were viable.
Cellular proliferation was determined by using the VybrantR MTT
cell proliferation assay kit (Molecular Probes, Invitrogen, Oregon,
USA). Absorbance determination at 570 nm was realized by using
a microplate reader; proliferation was expressed as stimulation
indices (SI = ratio of the mean proliferation of the cells after stim-
ulation relative to the proliferation of unstimulated control cells
from the same animal).
2.9. Statistical analyses
The Mann–Whitney U-test was used to determine possible sta-
tistical differences in oocysts shedding. Protection against oocysts
elimination in cats was evaluated by estimating the preventable
fraction (PF) as described (Garcia et al., 2007) with modiﬁcations:
PF = p2p1/p2; where p2 = mean of oocysts shedding among
group unvaccinated (G5) and p1 = mean of oocysts shedding
among group vaccinated (G1, G2, G3, or G4).
3. Results
3.1. Humoral immune response
The kinetics of the production of serum IgG, IgM, and IgA anti-
bodies is shown in Fig. 1 respectively. A comparative analysis of the
speciﬁc responses of each animal immunized by the nasal and rec-
tal routes is given (Table 2). When the production of IgG antibodies
was evaluated, it was observed that only G1 and G3 cats demon-
strated antibody concentrations at the time of challenge (day 70).
However, only one cat (G3) demonstrated antibody concentrations
above the cut-off level before being challenged (Fig. 1). Addition-
ally, cats from all groups except those from G5 had concentrations
of IgG antibodies above the cut-off level effective from day 85. In-
crease in the production of IgM antibodies above the cut-off level
before challenge only occurred in G1 cats, and was observed at
day 21 (n = 1), 63 (n = 2), and 70 (n = 2). The kinetics of the produc-
tion of IgM antibodies in most groups was increased above the cut-
off level effective from day 85, peaked at day 100, and declined at
the end of the experiment. Cats from other groups did not demon-
strate serum concentrations of IgM antibodies above the cut-off
level before being challenged at day 70. Cats from all groups did
not demonstrate concentrations of serum IgA antibodies beyond
the cut-off level before being challenged on day 70. Nevertheless,
the production of IgA antibodies above the cut-off level began
effective from day 85 for most groups, except for most cats of
group ﬁve whose concentrations of IgA surpassed that of the cut-
off point on day 100. Further, when the production of IgM and
IgG antibodies was compared, it was shown that cats from all
groups were seroconverted after being challenged (Fig. 1).
Cats immunized by the nasal route (G1) produced comparatively
more intestinal IgA antibodies (ODmean = 0.330, ODcut-off = 0.133)
relative to those vaccinated rectally (G3; ODmean = 0.167) by the
administration of rhoptry proteins (Fig. 2). However, cats from both
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Fig. 1. Serum IgG, IgM, and IgA antibody responses of cats evaluated by the indirect enzyme-linked immunosorbent assay. G1, vaccinated with rhoptry plus Quil-A by via
nasal; G2 received bovine serum albumin (BSA) plus Quil-A via nasal; G3 received rhoptry plus Quil-A via rectal; G4 received BSA plus Quil-A via rectal; G5 remained as
unvaccinated control. Treatments were made at days 0, 21, 42, and 63 ( ). All groups received a challenge of 800 cysts from the ME-49 strain on day 70 ( ). Dashed line
indicates positive cut-off (ODIgG = 0.195, ODIgM = 0.2, and ODIgA = 0.067).
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tinal IgA antibodies relative to those that were unvaccinated but
challenged (G5), whose production of IgA was below the cut-off le-
vel (Fig. 2).
3.2. Oocyst shedding
The comparative analyses of oocyst shedding, based on the
routes of vaccination, are illustrated in Fig. 3a and b. Signiﬁcant
statistical differences (p < 0.02) in oocyst shedding were observed
(Fig. 3a) when cats vaccinated by the nasal route (G1 and G2) were
compared to those used as controls (G5), where the liberation of
oocyst by G1 animals was signiﬁcantly reduced compared to those
from G2 (nasal controls) and G5 (unvaccinated, unchallenged cats).
However, signiﬁcant statistical differences were not demonstrated
(p > 0.3) when cats vaccinated by the rectal route (G3 and G4) were
compared to those of G5 (Fig. 3b).
The dynamics of parasitic infection and elimination based on
the prepatent (PPP) and patent (PP) periods, and the peak of oocyst
excretions is shown in Table 3. Cats vaccinated intranasallydemonstrated a longer PPP, but reduced PP when compared with
cats from other groups. The G1 animals excreted comparatively
less number of oocysts (93,750) and demonstrated a superior pre-
ventable fraction (98.4%) relative to those cats from other groups.
Additionally, the peak of oocyst shedding was comparatively re-
duced (4 days) in G1 cats relative to those from the other groups.
Further, G1 cats shed 87.4%, 96.5%, and 96.1% less oocysts than
G2, G3, and G4 cats, respectively (data not shown). There were
no correlation between the titers of antibodies and oocysts shed-
ding (Table 2). Animals from all groups shed oocysts after being
challenged. The animals from all groups did not demonstrate clin-
ical signs after challenge.
3.3. Lymphocyte proliferation
The overall degree of lymphocytic proliferation was more ele-
vated in cats vaccinated intranasally (G1) when compared to those
immunized via rectum (G3) (Fig. 4). However, only the vaccine with
5 lg/rhoptries/ml of PBMC of G1 demonstrated desirable stimula-
tion indexes. When the cellular immune response to animals
Table 2
Correlation between serum IgG and IgM, fecal IgA, and oocyst shedding of cats immunized with crude rhoptry proteins of T. gondii.
Experimental groups Animals Optical density of immunoglobulins Oocysts sheddingc Cellular immune response 70b
IgG (OD = 0.2)a IgM (OD = 0.22)a IgA (OD = 0.133)a
70b 21 63 70b 702
G1 (nasal) 01 0.056 0.164 0.01 0.01 0.770 26,250 Positive
02 0.391 0.094 0.206 0.457 0.258 2500
03 0.226 0.244 0.081 0.220 0.171 48,750
4 0.01 0.01 0.189 0.162 0.282 12,500
5 0.02 0.03 0.234 0.01 0.173 3750
Total 93,750
G3 (rectal) 11 0.221 0.01 0.021 0.037 0.054 380,000 Negative
12 0.088 0.05 0.133 0.065 0.079 81,250
13 0.083 0.081 0.132 0.108 0.089 1881,250
14 0.291 0.025 0.198 0.136 0.519 377,250
15 0.248 0.064 0.016 0.101 0.095 27,500
Total 2.747.250
a Cut-off values.
b Period during which the procedure was performed.
c Average totals of oocyst shedding/g of feces.
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Fig. 2. Fecal IgA antibody responses of cats on being challenged (day 70). Dashed
line indicates positive cut-off (OD = 0.133).
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shown that those cats inoculated intranasally demonstrated posi-
tive cellular response relative to those vaccinated via rectum,
whose response was negative (Table 2).4. Discussion
This study has demonstrated that the administration of crude
rhoptry proteins of T. gondii by the nasal and rectal routes was efﬁ-
cient in immunizing cats infected with oocysts of T. gondii. How-
ever, data has demonstrated that cats vaccinated intranasally
(G1) were more protected due to the comparatively superior pre-
ventable fraction, reduced oocysts shedding, and better immuno-
logical stimulation of IgA antibodies from feces and PBMCs
relative to those vaccinated via rectal (G3). Further, since G1 cats
eliminated less oocyst than other groups, the participation of local-
ized IgA and T cell responses could have contributed to the control
of T. gondii. It has been demonstrated that human secretory IgA
inhibits enterocyte penetration and replication of T. gondii
in vitro (Mack and McLeod, 1992) and in vivo (Bonefant et al.,
2001; Dimier-Poisson et al., 2006). Additionally, a previous study
has supported the role of mucosal CD8+ cell population in mucosal
protection of cats (Finerty et al., 2000).
During this study cats vaccinated intranasally (G1) liberated
98.4% less oocysts than those that were unvaccinated group (G5).However, a previous study did not report the shedding of oocyst
in 66.67% (2/3) of cats immunized intranasally after three doses
of a similar vaccine that obtained a preventable fraction of approx-
imately 67% (Garcia et al., 2007). Few additional studies have
investigated the immunization of T. gondii in cats: some have uti-
lized the T-263 live strain to evaluate oocyst shedding protection
in cats (Frenkel et al., 1991; Freyre et al., 1993; Mateus-Pinilla
et al., 1999); these studies have described reduced production of
T. gondii oocyst. Omata et al. (1996) evaluated a 60co-irradiated
tachyzoites vaccine in cats but only 21.42% (3/14) of infected cats
did not shed oocysts. Further, a study using DNA vaccine that ex-
pressed the recombinant ROP2 protein to immunize cats did not
indicate a reduction in oocysts shedding (Mishima et al., 2002).
However, one of the disadvantages of the T-263 vaccine is that it
contains live bradyzoites of T. gondii (Dubey, 1995); this strain
was also recommended for the vaccination of healthy cats (Choro-
manski et al., 1994). Therefore, the results of this study are impor-
tant due to the demonstration of optimal protection against
infective oocysts of T. gondii.
The risk of oocyst contamination by susceptible human popula-
tions has been described (Jones et al., 2006; Santos et al., 2010),
and must be underscored. Recent studies have demonstrated sero-
positivity to IgG and IgM of T. gondii in human populations residing
in Erechim, southern Brazil, where there was an elevated risk
(OR > 2.08) of infection for individuals that had previous contact
with soil (Jones et al., 2006). Additionally, an environmental survey
has suggested that 22.58% (7/31) of soil samples obtained from the
playgrounds of elementary public schools in the state of São Paulo
were positive for T. gondii, and it was concluded that T. gondii oo-
cysts are widely distributed within areas of public schools located
in that region (Santos et al., 2010). Further, an outbreak of human
toxoplasmosis was described in Santa Isabel do Ivai, Brazil, where
approximately 426 persons were infected, and the source of con-
tamination might have been the common access to water (de
Moura et al., 2006). Consequently, a vaccine that efﬁciently reduces
oocyst shedding in cats, as was demonstrated in this study, is
desirable and might have prevented infections due to environmen-
tal contamination.
Although no correlation between oocyst shedding and antibody
production was observed during this study, cats vaccinated intra-
nasally (G1) demonstrated more elevated levels of intestinal IgA
relative to those immunized via rectal (G3) and those that were
unvaccinated (G5). The absence of correlation between circulating
antibodies and intestinal immunity was described (Dubey and
Frenkel, 1972). It was previously demonstrated that only 25% of
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G3 5 0 0 28,75 138,75 187,5 300,0 376,25 300,0 77,25 552,5 437,5 312,5 26,25 2,5 1,25 2,5 2,5 1,25 0 2,747,25
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Fig. 3. Oocyst shedding in cats immunized with rhoptry proteins by the nasal (G1) and rectal (G3) route; G2 and G4 were adjuvant controls, and G5 unvaccinated control.
Challenged was performed at day 70 with 800 tissue cysts of ME-49 strain of T. gondii.
Table 3
Shedding of T. gondii oocyst in cats immunized with crude rhoptry proteins.
Experimental groups Pre-patent period
(days)
Patent Period
(days)
Peak of oocysts shedding (days) Total number of oocysts Preventable fraction
(%)
G1 (nasal vaccinated) 6.8 2.8 4 93,750 98.4
G2 (nasal control) 4.8 6 5 736,250 87.4
G3 (rectal vaccination) 4 9.6 11 2747,250 53
G4 (rectal control) 4.4 8.2 5 2453,750 58
G5 (unvaccinated,
challenged)
4.8 8.8 6 5850,000 Not determined
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Fig. 4. Comparative analyses of the cellular immune response of cats immunized
with rhoptry proteins by the nasal (G1) and rectal (G3) routes. Lymphocytes
stimulation indices (SI) using 5, 10 and 15 lg of rhoptries and Concavalin A
(10 mg/ml) as positive control.
D.L. Zulpo et al. / Experimental Parasitology 131 (2012) 223–230 229kittens had serum antibody after the ﬁrst challenge, and 71% at the
second, and it was reported that immunity occurred in the absence
of antibodies, particularly in cats treated with monesin (2/7) and
sulfadiazine (3/4) (Frenkel and Smith 1982). These authors have
suggested that oocyst formation per se is not necessary for cats
to be immunized. In another study, six cats were vaccinated with
the T-263 strain, none of these developed antibodies against T. gon-
dii, but four were immunized against oocyst shedding (Frenkel
et al. 1991). Further, it was suggested that the primary focus of
immunity to oocyst shedding might be the intestinal epithelium
of kittens (Frenkel et al., 1991). Therefore, the elevated intestinal
stimulation observed in cats vaccinated intranasally with the crude
rhoptry proteins of T. gondii during this study is of fundamental
importance.
The ME49 strain used during this study is a genotype II strain,
and is themost frequently utilized strain in evaluated in cats (Dubey
and Thulliez, 1989; Lappin et al., 1989, 1994; Burney et al., 1995;
Dubey et al., 1995; Dubey, 1995; Garcia et al., 2007). This strain
has produced large quantities of brain cysts in mice and oocysts in
cats (Dubey, 1995). The peaks of oocysts shedding herein described
(from all groups) were similar to previously described studies,
where the PPP varied between 3 and 7 days, with PP ranging from
5–19 days. However, during this study, the PP of intranasally vacci-
nated cats (G1) was remarkably reduced (PPG1 = 2.8 days) when
compared to that of other groups. The results of this study are highly
desirable since environmental contamination by oocyst can be sig-
niﬁcantly reduced. Consequently, the development of a vaccine
aimed at controlling oocyst shedding in cats, as occurred during this
study, would be of utmost importance to control toxoplasmosis in
either human or animal populations.The cats from this study did not demonstrate clinical symp-
toms; similar results have been described (Dubey and Thulliez,
1989; Lappin et al. 1994; Burney et al., 1995; Garcia et al., 2007).
However, intermittent diarrhea and acute toxoplasmosis have
been described after experimental infection in kittens <6-month-
old with ME49 strain (Lappin et al., 1989; Dubey et al., 1995; Du-
bey, 1995). Clinical manifestations of toxoplasmosis in cats is di-
rectly related to factors such as the age, time of primary
infection, the strain, the stage and the route of infection, nutritional
status, and concurrent infections (Dubey, 1995).
In conclusion, we have observed that nasal immunization with
crude rhoptry proteins of T. gondii in cats, using Quil-A as an adju-
vant, was able to stimulate a response in PBMCs and intestinal IgA
and partially protect animals from oocyst shedding.
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